<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468607</url>
  </required_header>
  <id_info>
    <org_study_id>GO41751</org_study_id>
    <nct_id>NCT04468607</nct_id>
  </id_info>
  <brief_title>A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will
      make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with
      locally advanced or metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 8, 2020</start_date>
  <completion_date type="Anticipated">January 2, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Nature of DLTs</measure>
    <time_frame>Approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patricipants with Adverse Events</measure>
    <time_frame>Approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Cycles Received</measure>
    <time_frame>Approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Intensity</measure>
    <time_frame>Approximately 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose(s) MTD(s) of BLYG8824A</measure>
    <time_frame>Approximately 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of BLYG8824A</measure>
    <time_frame>At predifined interevals from Cycle 1 Day 1; Cycle 2 Day 1; Cycles ≥ 3, Day 1; Treatment Completion/ Discontinuation (Cycle length: 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Duration of response (DOR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Anti-drug Antibodies (ADAs)</measure>
    <time_frame>Cycle 1, Day 1; Cycle 2 Day 1; Cycles ≥ 3, Day 1; Treatment Completion/ Discontinuation (Cycle length: 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose-Escalation Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Expansion Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLYG8824A</intervention_name>
    <description>BLYG8824A will be administered at a flat dose independent of body weight.</description>
    <arm_group_label>Dose-Escalation Stage</arm_group_label>
    <arm_group_label>Dose-Expansion Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status of 0 or 1

          -  Life expectancy of at least 12 weeks

          -  Histologically or cytologically documented invasive CRC: incurable, unresectable,
             locally advanced or metastatic CRC previously treated with multimodality therapy or
             mCRC

          -  Locally advanced or metastatic CRC that has relapsed or is refractory to established
             therapies

          -  Prior disease progression (or intolerance) following oxaliplatin, irinotecan,
             fluoropyrimidines, and anti-EGFR monoclonal antibodies

          -  An archival tissue specimen or fresh baseline biopsy (when archival is not available)
             is required for enrollment into the study

          -  Measurable disease, according to the Response Evaluation Criteria in Solid Tumors
             (RECIST) v1.1. Non-measurable evaluable disease is acceptable for dose-escalation.

          -  Adequate hematologic and end organ function

          -  Acute, clinically significant treatment-related toxicity from prior therapy resolved
             to Grade ≤ 1 prior to study entry

        Expansion Cohort-Specific Inclusion Criteria

          -  MSS or MSI-L disease as determined by polymerase chain reaction (PCR) and/or IHC

          -  Measurable disease by RECIST v1.1 with at least one measurable target lesion in the
             expansion cohort

          -  Progression must have occurred during or after most recent treatment for locally
             advanced or metastatic colorectal cancer

        Exclusion Criteria:

          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within
             4 months after the final dose of BLYG8824A

          -  Significant cardiopulmonary dysfunction

          -  Known clinically significant liver disease

          -  Positive serologic or PCR test results for acute or chronic HBV infection

          -  Acute or chronic HCV infection

          -  HIV seropositivity

          -  Poorly controlled Type 2 diabetes mellitus

          -  Current treatment with medications that are well known to prolong the QT interval

          -  Primary CNS malignancy, untreated CNS metastases, or active CNS metastases

          -  Leptomeningeal disease

          -  Spinal cord compression that has not been definitively treated with surgery and/or
             radiation

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO41751 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre; Medical Oncology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra; Servicio de Farmacia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz; START Madrid-FJD, Servicio de Farmacia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

